Tandem CAR T-cells more than doubled event-free survival in transplant-ineligible lymphoma

Design

Open-label randomised phase 2 trial

Population

160 transplant-ineligible adults with relapsed or refractory large B-cell lymphoma, median age 74

Primary outcome

Event-free survival by blinded independent review

Effect

6.2 vs 2.5 months; HR 0.39 (95% CI 0.27–0.58)

DALY 2-EU, an open-label randomised phase 2 trial at 45 European centres, enrolled 160 adults with relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy who were ineligible for transplantation. Median age was 74. Patients received a single infusion of zamtocabtagene autoleucel — fresh, non-cryopreserved CAR T-cells targeting both CD20 and CD19 — or up to eight cycles of rituximab, gemcitabine and oxaliplatin (R-GemOx).

Median vein-to-vein time was 15 days. At a median 17 months, event-free survival, judged by a blinded committee, was 6.2 months with CAR T-cells against 2.5 months with R-GemOx (HR 0.39). Severe adverse events were common in both arms; cytokine release syndrome (8%) and neurotoxicity (5%) occurred only with CAR T-cells. There were two treatment-related deaths with CAR T-cells and one with R-GemOx.

Anti-CD19 CAR T-cell therapy is standard second-line treatment for fitter patients, but older patients who cannot have a transplant have had no randomised evidence. This trial gives it. Short manufacturing time with a fresh product also matters for patients whose disease progresses quickly.

It is a phase 2 trial with event-free survival as the end point; overall survival data are immature. Access in India is limited by cost and manufacturing, though locally developed CAR T-cell products are now approved.

• Refer transplant-ineligible patients with relapsed large B-cell lymphoma to a CAR T-cell centre for assessment early.
• Do not exclude older patients from CAR T-cell discussion on age alone; the median age here was 74.
• Counsel on cytokine release syndrome and neurotoxicity and the need to stay near the treating centre.
• Consider R-GemOx or other options where CAR T-cell therapy is not accessible.

Why it matters

It extends CAR T-cell therapy, with randomised evidence, to older patients previously limited to palliative chemoimmunotherapy.

Don't overread it

Phase 2 with immature survival data; it is not yet proof of longer life.

The statistics, in plain English

A hazard ratio of 0.39 means about 60% lower risk of an event (progression, new treatment or death) at any time. The confidence interval (0.27 to 0.58) is well clear of 1. Event-free survival is not overall survival, which remains to be reported.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.